NeuroPace FY2025 EPS Estimate Decreased by Cantor Fitzgerald

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for NeuroPace in a report issued on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.80) per share for the year, down from their prior estimate of ($0.79). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. During the same quarter in the prior year, the business posted ($0.28) earnings per share.

NPCE has been the topic of a number of other research reports. UBS Group initiated coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company upped their price objective on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Stock Performance

NeuroPace stock opened at $14.19 on Friday. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.15. The company’s 50-day moving average price is $11.75 and its two-hundred day moving average price is $8.81. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after acquiring an additional 6,181 shares in the last quarter. Financial Advocates Investment Management lifted its holdings in shares of NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of NeuroPace in the fourth quarter worth $129,000. Barclays PLC grew its holdings in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares in the last quarter. Finally, State Street Corp raised its position in NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after buying an additional 12,912 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the sale, the insider now owns 87,062 shares in the company, valued at approximately $1,306,800.62. The trade was a 3.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.20% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.